Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
GLP-1 receptor agonists should be considered when patients experience significant weight regain with BMI 27 kg/m with obesity-related comorbidities or BMI 30 kg/m, lifestyle modifications have been insufficient, no anatomical complications require surgical revision, and patients are willing to engage in long-term pharmacotherapy
Long-term success depends not on any one drug, but on the totality of care options provided
Specialist Brands: Geri-Care , Reliable 1 Laboratories , Oncor Pharmaceuticals , Health Star , and CareSens
ACS Chem Neurosci 16:818825 Dickson SL, Shirazi RH, Hansson C et al (2012) The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
